keyword
MENU ▼
Read by QxMD icon Read
search

Lymphoma

keyword
https://www.readbyqxmd.com/read/28823098/modified-rapid-immunohistochemical-staining-for-intraoperative-diagnosis-of-malignant-brain-tumors
#1
Akane Suzuki, Takashi Maruyama, Masayuki Nitta, Takashi Komori, Soko Ikuta, Takakazu Kawamata, Yoshihiro Muragaki
Rapid immunohistochemistry (R-IHC) has been developing mainly as a support technique in the rapid diagnosis of central nervous system tumors; however, there have been problems regarding instability in specimen preparation and immunostaining. To overcome the weakness of this technology, the instability of immunostaining, we developed a modified R-IHC. This was achieved by switching to 4% paraformaldehyde as the fixative solution and utilizing a commercially available Polymer Refine Detection Kit, as a high-sensitivity kit, in place of the secondary antibodies...
August 19, 2017: Brain Tumor Pathology
https://www.readbyqxmd.com/read/28823027/a-prospective-study-of-palonosetron-for-prevention-of-chemotherapy-induced-nausea-and-vomiting-in-malignant-lymphoma-patients-following-highly-emetogenic-chemotherapy
#2
Tsutomu Takahashi, Takahiro Okada, Fumiyoshi Ikejiri, Shunsuke Ito, Yusuke Okada, Fumimasa Takahashi, Satoshi Kumanomido, Yumi Jo, Koji Adachi, Chie Onishi, Koshi Kawakami, Takaaki Miyake, Masaya Inoue, Ritsuro Suzuki, Junji Suzumiya
BACKGROUND: Chemotherapy-induced nausea and vomiting (CINV) is a troublesome issue in chemotherapy for cancer patients. A second-generation 5HT3 receptor antagonist (5HT3RA), palonosetron, is effective and safe for the prevention of CINV in breast cancer patients treated with cyclophosphamide and anthracycline, but there is little data for malignant lymphoma. We conducted a prospective phase 2 study at a single institution to clarify the efficacy and safety of palonosetron in lymphoma patients...
August 19, 2017: International Journal of Clinical Oncology
https://www.readbyqxmd.com/read/28822981/spectrum-of-lymphomas-across-different-drug-treatment-groups-in-rheumatoid-arthritis-a-european-registries-collaborative-project
#3
Louise K Mercer, Anne C Regierer, Xavier Mariette, William G Dixon, Eva Baecklund, Karin Hellgren, Lene Dreyer, Merete Lund Hetland, René Cordtz, Kimme Hyrich, Anja Strangfeld, Angela Zink, Helena Canhao, M Victoria Hernandez, Florence Tubach, Jacques-Eric Gottenberg, Jacques Morel, Jakub Zavada, Florenzo Iannone, Johan Askling, Joachim Listing
BACKGROUND: Lymphomas comprise a heterogeneous group of malignant diseases with highly variable prognosis. Rheumatoid arthritis (RA) is associated with a twofold increased risk of both Hodgkin's lymphoma (HL) and non-Hodgkin's lymphoma (NHL). It is unknown whether treatment with biologic disease-modifying antirheumatic drugs (bDMARDs) affect the risk of specific lymphoma subtypes. METHODS: Patients never exposed to (bionaïve) or ever treated with bDMARDs from 12 European biologic registers were followed prospectively for the occurrence of first ever histologically confirmed lymphoma...
August 19, 2017: Annals of the Rheumatic Diseases
https://www.readbyqxmd.com/read/28822906/the-impact-of-htlv-1-on-the-cellular-genome
#4
REVIEW
Lucy Cook, Anat Melamed, Hiroko Yaguchi, Charles Rm Bangham
Human T-lymphotropic virus type-1 (HTLV-1) is the causative agent of adult T-cell leukaemia/lymphoma (ATL), an aggressive CD4+ T-cell malignancy. The mechanisms of leukaemogenesis in ATL are incompletely understood. Insertional mutagenesis has not previously been thought to contribute to the pathogenesis of ATL. However, the recent discovery that HTLV-1 binds the key chromatin architectural protein CTCF raises the hypothesis that HTLV-1 deregulates host gene expression by causing abnormal chromatin looping, bringing the strong HTLV-1 promoter-enhancer near to host genes that lie up to 2Mb from the integrated provirus...
August 17, 2017: Current Opinion in Virology
https://www.readbyqxmd.com/read/28822887/the-changing-diagnostic-pathway-for-lung-cancer-patients-in-shanghai-china
#5
REVIEW
Tao Jiang, Shengxiang Ren, Xuefei Li, Chunxia Su, Caicun Zhou, Mary O'Brien
Accumulating evidence suggest that patients with advanced non-small-cell lung cancer (NSCLC) and specific genomic alterations including epidermal growth factor receptor and microtubule-associated protein-like 4 anaplastic lymphoma kinase could significantly benefit from molecular-targeted therapies compared with chemotherapy. Recently, immunotherapy based on programmed cell death 1 (PD-1) and its ligand (PD-L1) blockade prolong survival in patients with advanced NSCLC, especially in those patients with positive expression of PD-L1 and when used in the first-line setting...
August 17, 2017: European Journal of Cancer
https://www.readbyqxmd.com/read/28822832/combined-immunodeficiency-with-ebv-positive-b-cell-lymphoma-and-epidermodysplasia-verruciformis-due-to-a-novel-homozygous-mutation-in-rasgrp1
#6
Craig D Platt, Ari J Fried, Rodrigo Hoyos-Bachiloglu, G Naheed Usmani, Birgitta Schmidt, Jennifer Whangbo, Roberto Chiarle, Janet Chou, Raif S Geha
RASGRP1 is a guanine-nucleotide-exchange factor essential for MAP-kinase mediated signaling in lymphocytes. We report the second case of RASGRP1 deficiency in a patient with a homozygous nonsense mutation in the catalytic domain of the protein. The patient had epidermodysplasia verruciformis, suggesting a clinically important intrinsic T cell function defect. Like the previously described patient, our proband also presented with CD4(+) T cell lymphopenia, impaired T cell proliferation to mitogens and antigens, reduced NK cell function, and EBV-associated lymphoma...
August 16, 2017: Clinical Immunology: the Official Journal of the Clinical Immunology Society
https://www.readbyqxmd.com/read/28822443/-follicular-lymphoma-with-minimal-change-nephrotic-syndrome-in-a-child
#7
Z B Yang, Y Liu, Z H Zhang
No abstract text is available yet for this article.
August 2, 2017: Zhonghua Er Ke za Zhi. Chinese Journal of Pediatrics
https://www.readbyqxmd.com/read/28822237/beyond-genomics-targeting-the-epigenome-in-diffuse-large-b-cell-lymphoma
#8
REVIEW
Andrea Kühnl, David Cunningham, Ian Chau
After decades of intense research on genetic alterations in cancer and successful implementation of genetically-based targeted therapies, the field of cancer epigenetics is only beginning to be fully recognized. The discovery of frequent mutations in genes modifying the epigenome in diffuse large B-cell lymphoma (DLBCL) has highlighted the outstanding role of epigenetic deregulation in this disease. Identification of epigenetically-driven DLBCL subgroups and development of novel epigenetic drugs have rapidly advanced...
August 9, 2017: Cancer Treatment Reviews
https://www.readbyqxmd.com/read/28822058/immune-dysfunction-in-non-hodgkin-lymphoma-avenues-for-new-immunotherapy-based-strategies
#9
REVIEW
Lorenzo Falchi
PURPOSE OF THIS REVIEW: The present review focuses on key aspects of non-Hodgkin lymphoma (NHL) evasion of immune surveillance and how these can be leveraged to devise effective immunotherapy strategies. RECENT FINDINGS: In recent years, significant progress has been made in the field of cancer immunotherapy. In particular, the remarkable clinical results of anti-programmed death (PD)-1/PD-ligand (L)1 antibodies are revolutionizing the treatment approach to multiple solid and hematologic tumors...
August 18, 2017: Current Hematologic Malignancy Reports
https://www.readbyqxmd.com/read/28821195/atypical-igg4-plasmacytic-proliferations-and-lymphomas-characterization-of-11-cases
#10
Jacob R Bledsoe, Zachary S Wallace, Vikram Deshpande, Joshua R Richter, Jason Klapman, Andrew Cowan, John H Stone, Judith A Ferry
Objectives: To report the clinicopathologic features of monotypic immunoglobulin G4+ (IgG4+) lymphoid and plasmacytic proliferations. Methods: Cases were identified from the pathology files. Pathology and clinical materials were reviewed. Results: Eleven cases of monotypic IgG4+ proliferations were identified at nodal, orbital, or salivary sites. Six cases (three men, three women; age, 57-94 years) met criteria for lymphoma or plasma cell neoplasia...
September 1, 2017: American Journal of Clinical Pathology
https://www.readbyqxmd.com/read/28820310/orbital-mantle-cell-lymphoma-presenting-as-myasthenia-gravis
#11
Justin Karlin, Travis Peck, Karyn Prenshaw, Craig A Portell, Maria Kirzhner
A 69-year-old man, previously treated with pyridostigmine for myasthenia gravis (manifesting as ptosis and diplopia) was evaluated for several concomitant bilateral anterior orbital masses. Imaging revealed 3 discrete, solid masses within and around the orbits. An incisional biopsy demonstrated atypical lymphocytes positive for CD20 and Cyclin-D1, consistent with mantle cell lymphoma. The patient received induction chemotherapy with a rituximab-based regimen. He experienced resolution of his diplopia and ptosis after one cycle of chemotherapy and achieved complete remission of the orbital masses and myasthenia symptoms after 6 cycles...
August 18, 2017: Orbit
https://www.readbyqxmd.com/read/28819821/anti-pd-1-antibodies-as-a-therapeutic-strategy-in-classical-hodgkin-lymphoma
#12
REVIEW
Michael D Jain, John Kuruvilla
Classical Hodgkin lymphoma (cHL) is defined by malignant Reed-Sternberg (RS) cells that recruit non-malignant immune cells into a supportive tumour microenvironment. In cHL, this is driven, in part, by genomic alterations of the 9p24.1 locus encoding the immune checkpoint ligands PD-L1 and PD-L2. Therapeutic anti-PD-1 antibodies have been developed that competitively inhibit the interaction between PD-1 and its ligands. Clinical trials of anti-PD-1 antibodies in cHL demonstrate high overall response rates but relapses still occur and new clinical challenges exist for toxicity management and response assessment...
August 17, 2017: Drugs
https://www.readbyqxmd.com/read/28819740/inotuzumab-ozogamicin-first-global-approval
#13
Yvette N Lamb
Intravenous inotuzumab ozogamicin (Besponsa(®); Pfizer) is an anti-CD22 monoclonal antibody-calicheamicin conjugate that binds to CD22-expressing tumour cells. Upon binding, the complex is internalised and the cytotoxic calicheamicin derivative is released inside the cell, inducing double-strand DNA breakage and subsequent cell death. In June 2017, the EMA granted inotuzumab ozogamicin approval as monotherapy for the treatment of adults with relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukaemia (ALL)...
August 17, 2017: Drugs
https://www.readbyqxmd.com/read/28819461/new-developments-in-the-pathology-of-malignant-lymphoma-a-review-of-the-literature-published-from-january-to-april-2017
#14
REVIEW
J Han van Krieken
No abstract text is available yet for this article.
March 2017: Journal of Hematopathology
https://www.readbyqxmd.com/read/28819186/cd24-induces-changes-to-the-surface-receptors-of-b-cell-microvesicles-with-variable-effects-on-their-rna-and-protein-cargo
#15
D Craig Ayre, Ian C Chute, Andrew P Joy, David A Barnett, Andrew M Hogan, Marc P Grüll, Lourdes Peña-Castillo, Andrew S Lang, Stephen M Lewis, Sherri L Christian
The CD24 cell surface receptor promotes apoptosis in developing B cells, and we recently found that it induces B cells to release plasma membrane-derived, CD24-bearing microvesicles (MVs). Here we have performed a systematic characterization of B cell MVs released from WEHI-231 B lymphoma cells in response to CD24 stimulation. We found that B cells constitutively release MVs of approximately 120 nm, and that CD24 induces an increase in phosphatidylserine-positive MV release. RNA cargo is predominantly comprised of 5S rRNA, regardless of stimulation; however, CD24 causes a decrease in the incorporation of protein coding transcripts...
August 17, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28819025/mre11-promotes-tumorigenesis-by-facilitating-resistance-to-oncogene-induced-replication-stress
#16
Elizabeth Spehalski, Kayla M Capper, Cheryl J Smith, Mary J Morgan, Maria Dinkelmann, Jeffrey Buis, JoAnn M Sekiguchi, David O Ferguson
Hypomorphic mutations in the genes encoding the MRE11/RAD50/NBS1 (MRN) DNA repair complex lead to cancer-prone syndromes. MRN binds DNA double strand breaks where it functions in repair and triggers cell cycle checkpoints via activation of the ataxia-telangiectasia mutated (ATM) kinase. To gain understanding of MRN in cancer, we engineered mice with B lymphocytes lacking MRN, or harboring MRN in which MRE11 lacks nuclease activities. Both forms of MRN deficiency led to hallmarks of cancer, including oncogenic translocations involving c-Myc and the immunoglobulin locus...
August 17, 2017: Cancer Research
https://www.readbyqxmd.com/read/28819011/tp53-mutations-identify-younger-mantle-cell-lymphoma-patients-who-do-not-benefit-from-intensive-chemoimmunotherapy
#17
Christian W Eskelund, Christina Dahl, Jakob W Hansen, Maj Westman, Arne Kolstad, Lone B Pedersen, Carmen P Montano-Almendras, Simon Husby, Catja Freiburghaus, Sara Ek, Anja Pedersen, Carsten Niemann, Riikka Räty, Peter Brown, Christian H Geisler, Mette K Andersen, Per Guldberg, Mats Jerkeman, Kirsten Grønbæk
Despite recent advances in lymphoma treatment, mantle cell lymphoma (MCL) remains incurable and we are still unable to identify patients who will not benefit from the current standard-of-care. Here, we explore the prognostic value of recurrent genetic aberrations in diagnostic bone marrow (BM) specimens from 183 younger MCL patients from the Nordic MCL2 and MCL3 trials, which represent current standard-of-care regimens. In the univariate model, mutations of TP53 (11%) and NOTCH1 (4%), and deletions of TP53 (16%) and CDKN2A (20%) were significantly associated with inferior outcomes (together with MIPI, MIPI-c, Blastoid morphology and Ki67>30%); however, in multivariate analyses only TP53 mutations (HR=6...
August 17, 2017: Blood
https://www.readbyqxmd.com/read/28818202/risk-of-arterial-thromboembolism-in-patients%C3%A2-with%C3%A2-cancer
#18
Babak B Navi, Anne S Reiner, Hooman Kamel, Costantino Iadecola, Peter M Okin, Mitchell S V Elkind, Katherine S Panageas, Lisa M DeAngelis
BACKGROUND: The risk of arterial thromboembolism in patients with cancer is incompletely understood. OBJECTIVES: The authors aimed to better define this epidemiological relationship, including the effects of cancer stage. METHODS: Using the Surveillance Epidemiology and End Results-Medicare linked database, the authors identified patients with a new primary diagnosis of breast, lung, prostate, colorectal, bladder, pancreatic, or gastric cancer or non-Hodgkin lymphoma from 2002 to 2011...
August 22, 2017: Journal of the American College of Cardiology
https://www.readbyqxmd.com/read/28818111/estimates-of-cancer-incidence-and-mortality-in-china-2013
#19
Rongshou Zheng, Hongmei Zeng, Siwei Zhang, Wanqing Chen
INTRODUCTION: Population-based cancer registration data are collected by the National Central Cancer Registry in China every year. Cancer incident cases and cancer deaths in 2013 were analyzed. METHODS: Through the procedure of quality control, reported data from 255 registries were accepted to establish the national database for cancer estimates. Incidences and mortalities were calculated with stratification by area (urban/rural), sex (male/female), age group (0, 1-4, 5-9, 10-14 … 80-84, and 85-year-old and above), and cancer site...
August 17, 2017: Chinese Journal of Cancer
https://www.readbyqxmd.com/read/28817403/primary-bone-lymphoma-exhibits-a-favorable-prognosis-and-distinct-gene-expression-signatures-resembling-diffuse-large-b-cell-lymphoma-derived-from-centrocytes-in-the-germinal-center
#20
Xin Li, Zijun Y Xu-Monette, Shuhua Yi, Bouthaina S Dabaja, Ganiraju C Manyam, Jason Westin, Nathan Fowler, Roberto N Miranda, Mingzhi Zhang, Judith A Ferry, L Jeffrey Medeiros, Nancy L Harris, Ken H Young
Primary bone (PB) diffuse large B-cell lymphoma (DLBCL) is rare and has a favorable prognosis, but the underlying biological mechanisms remain unknown. In this study we analyzed the clinicopathologic features of 160 patients with PB-DLBCL in comparison with 499 nonosseous DLBCL. Compared with patients with nonosseous DLBCL and secondary involvement of bone by DLBCL, PB-DLBCL patients less frequently had elderly age, B-symptoms, elevated serum lactate dehydrogenase levels, and high International Prognostic Index at diagnosis, more frequently had germinal center (GC) subtype (approximately 90%) and complete remission, and had significantly better survival...
August 16, 2017: American Journal of Surgical Pathology
keyword
keyword
958
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"